Pharmacological reversal of synaptic plasticity deficits in the mouse model of Fragile X syndrome by group II mGluR antagonist or lithium treatment
Name
Bear_Pharmacological reversal.pdf
Size
1.12 MB
Format
Adobe PDF
Checksum (MD5)
6a535378b494315f5be7a27a51178ad6
Author(s)
Choi, Catherine H.
Schoenfeld, Brian P.
Bell, Aaron J.
Hinchey, Paul
Kollaros, Maria
Gertner, Michael J.
Woo, Newton H.
Tranfaglia, Michael R.
Zukin, R. Suzanne
McDonald, Thomas V.
Date Issued
November 2010
Journal
Brain Research
Publisher
Elsevier
Citation
Choi, Catherine H., Brian P. Schoenfeld, Aaron J. Bell, Paul Hinchey, Maria Kollaros, Michael J. Gertner, Newton H. Woo, et al. “Pharmacological Reversal of Synaptic Plasticity Deficits in the Mouse Model of Fragile X Syndrome by Group II mGluR Antagonist or Lithium Treatment.” Brain Research 1380 (March 2011): 106–119.
Version
Author's final manuscript
Abstract
Fragile X syndrome is the leading single gene cause of intellectual disabilities. Treatment of a Drosophila model of Fragile X syndrome with metabotropic glutamate receptor (mGluR) antagonists or lithium rescues social and cognitive impairments. A hallmark feature of the Fragile X mouse model is enhanced mGluR-dependent long-term depression (LTD) at Schaffer collateral to CA1 pyramidal synapses of the hippocampus. Here we examine the effects of chronic treatment of Fragile X mice in vivo with lithium or a group II mGluR antagonist on mGluR-LTD at CA1 synapses. We find that long-term lithium treatment initiated during development (5–6 weeks of age) and continued throughout the lifetime of the Fragile X mice until 9–11 months of age restores normal mGluR-LTD. Additionally, chronic short-term treatment beginning in adult Fragile X mice (8 weeks of age) with either lithium or an mGluR antagonist is also able to restore normal mGluR-LTD. Translating the findings of successful pharmacologic intervention from the Drosophila model into the mouse model of Fragile X syndrome is an important advance, in that this identifies and validates these targets as potential therapeutic interventions for the treatment of individuals afflicted with Fragile X syndrome.
MIT Department
Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
Picower Institute for Learning and Memory
Terms of Use
Creative Commons Attribution-Noncommercial-NoDerivatives
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.brainres.2010.11.032
